SCHEMBL20799779

SCHEMBL20799779

Cc1sccc1CCNc1nnc(NCc2cc(CCNc3nnc(N)[nH]3)cs2)[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14869249 0.85 PNP (0.32)
SCHEMBL20799778 0.81
SCHEMBL14869159 0.78 PNP (0.38)
SCHEMBL14869314 0.75 ABL1 (0.31)
SCHEMBL20799780 0.75
SCHEMBL19165010 0.71 GPR84 (0.36)
SCHEMBL14869342 0.69 GAA (0.30)
SCHEMBL14869230 0.68 PNP (0.42)
SCHEMBL14869194 0.68 PNP (0.32)
SCHEMBL14869338 0.66 ALOX5 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10668031-B2 Biguanide compositions and methods of treating metabolic disorders ANJI PHARMA (US) LLC (US) 2020-06-02 US disclosed
US-20190076380-A1 Biguanide Compositions and Methods of Treating Metabolic Disorders ANJI PHARMACEUTICALS INC. 2019-03-14 US disclosed